Welcome to our dedicated page for Becton Dickinson & Co news (Ticker: BDX), a resource for investors and traders seeking the latest updates and insights on Becton Dickinson & Co stock.
Becton, Dickinson and Company (BD) (NYSE: BDX) is a global medical technology company whose news flow reflects activity across medical discovery, diagnostics, drug delivery and interventional care. On this page, readers can follow company-issued updates and third-party coverage related to BD’s operations, product clearances, collaborations and corporate developments.
Recent BD news highlights regulatory milestones, such as U.S. FDA 510(k) clearance for the EnCor EnCompass™ Breast Biopsy and Tissue Removal System, a multi-modality breast biopsy platform designed to support early detection and diagnosis of breast disease. Other announcements showcase BD’s role in supporting the pharmaceutical supply chain, including investments to expand production of BD Neopak™ Glass Prefillable Syringes in the United States to help meet growing demand for biologic and GLP-1 drug delivery.
Investors and observers can also track BD’s clinical and surgical innovations, including milestones with Phasix™ Mesh for hernia prevention in Europe and progress in the PREVENT trial, as well as the European launch of the BD Surgiphor™ Surgical Wound Irrigation System. In diagnostics and research, BD reports collaborations with institutions such as the University of Pennsylvania’s Institute for Immunology and Immune Health, and product updates like new IVDR-certified VIASURE assays for the BD MAX™ System and expanded configurations of BD FACSDiscover™ A8 Cell Analyzers.
Corporate governance and financial communications feature in BD’s news as well, with items such as leadership appointments in investor relations and notices regarding annual shareholder meetings. This news feed offers a centralized view of BD’s product pipeline, strategic investments, partnerships and regulatory events, providing context for how the company positions itself within the medical technology landscape.
Becton, Dickinson and Company (NYSE: BDX) announced on August 22, 2022, the pricing for its Tender Offers to purchase up to $500,000,000 in cash of various senior notes and debentures. The offers include securities due between 2027 and 2050, with specified total consideration amounts, including early tender payments. The early tender date was set for August 19, 2022, with an early settlement date on August 23, 2022. The company aims to enhance financial flexibility through these transactions while ensuring specific limits on the amounts purchased for each series.
Becton, Dickinson and Company (NYSE: BDX) reported early tender results for its debt securities tender offers, announcing an increase in the Offer SubCap for the 3.794% Senior Notes due 2050 from $175 million to $190 million. The company is seeking to purchase up to $500 million in various securities, with significant participation noted by the early tender date of August 19, 2022. Notably, all conditions for the tender offers were satisfied, with payment for accepted securities scheduled for August 23, 2022. The offer details are outlined in the Offer to Purchase.
BD (Becton, Dickinson and Company) and Accelerate Diagnostics, Inc. have formed a global commercial collaboration to provide rapid antimicrobial identification and susceptibility diagnostics. This partnership allows BD to market the Accelerate Pheno® system and Arc™ module, which offer quicker results compared to traditional testing methods. The collaboration aims to enhance patient care by optimizing antibiotic use, potentially reducing healthcare costs, and addressing antimicrobial resistance. This initiative is expected to increase market penetration for both companies, improving healthcare outcomes globally.
BD (Becton, Dickinson and Company) has entered into a collaboration with Labcorp to develop flow cytometry-based companion diagnostics (CDx) aimed at improving cancer treatment outcomes. This strategic partnership combines BD's expertise in flow cytometry with Labcorp's strengths in diagnostics and drug development, creating a comprehensive solution for the pharmaceutical industry. The collaboration will facilitate the development and commercialization of CDx, enhancing patient access to personalized therapies.
Becton, Dickinson and Company (NYSE: BDX) has announced tender offers to purchase up to $500 million of its outstanding debt securities. The offers include several series of securities with varying due dates ranging from 2027 to 2050. Holders must tender their securities by 5:00 p.m. on August 19, 2022, to be eligible for early tender payment. The tender offers will expire on September 2, 2022. The total consideration for securities will be determined based on fixed spreads over U.S. Treasury securities. This move aims to manage debt effectively amid changing market conditions.
BD (Becton, Dickinson and Company) has partnered with Direct Relief and the National Association of Community Health Centers (NACHC) to allocate $1.08 million to four community health centers. This funding aims to improve chronic disease management for underserved populations. Each center will receive $270,000 to enhance culturally sensitive care and pharmacist-led education. The initiative, part of the BD Helping Build Healthy Communities program, has supported 52 centers since 2013, totaling $22.6 million in contributions.
BD (Becton, Dickinson and Company) reported revenue of $4.6 billion for Q3 2022, a 0.7% increase year-over-year. Base revenue growth was 6.0%, with a notable decline in COVID-only testing revenues to $76 million from $300 million previously. GAAP diluted EPS was $1.28, while adjusted EPS rose 16.7% to $2.66. The company raised its full-year revenue guidance to approximately $18.75-$18.83 billion, reflecting 8.75%-9.25% growth, and adjusted EPS guidance to $11.28-$11.35. BD's ongoing acquisitions and innovations support its growth strategy amid macroeconomic challenges.
BD (Becton, Dickinson and Company) has acquired MedKeeper, a provider of cloud-based pharmacy management applications, enhancing its commitment to Smart, Connected Care. This strategic acquisition aims to optimize IV workflow by integrating MedKeeper's solutions into BD's existing medication management offerings. The move addresses the growing need for customizable pharmacy software in light of COVID-related challenges. The transaction is expected to have an immaterial impact on BD's fiscal 2022 financial results.
BD (Becton, Dickinson and Company) has launched a new molecular PCR test for the monkeypox virus, now available for research use outside the U.S. This test leverages the BD MAX™ System, providing fast and efficient results for laboratories. The BD MAX™ platform can process up to 24 samples in under three hours. This initiative, developed in partnership with CerTest Biotec, aims to enhance research capabilities amidst a global health emergency declared by the World Health Organization. This test is critical for understanding and controlling the spread of monkeypox.
The Board of Directors of BD (Becton, Dickinson and Company) has declared a quarterly dividend of $0.87 per common share, payable on September 30, 2022, to shareholders on record as of September 9, 2022. This results in an annual dividend rate of $3.48 per share, reflecting the company's commitment to returning value to its shareholders. BD continues to advance global health through innovative medical technology, ensuring safety and efficiency in healthcare delivery.